Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Biocept Inc

(NASDAQ: BIOC)
Add to Portfolio
-0.02 (-2.55%)
as of Nov 14, 2019

Biocept Reports Third Quarter 2019 Financial Results

PR Newswire via COMTEX - Wed Nov 13, 04:05PM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the(full story)
BIOC: 0.65 (-0.02)

Biocept Announces CE IVD Marks and Availability of its

PR Newswire via COMTEX - Thu Nov 07, 08:05AM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces CE (Conf(full story)
BIOC: 0.65 (-0.02)

Biocept to Release Third Quarter 2019 Financial

PR Newswire via COMTEX - Wed Nov 06, 08:05AM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it (full story)
BIOC: 0.65 (-0.02)

Biocept's Target Selector(TM) Tests and Kits to Be

PR Newswire via COMTEX - Mon Nov 04, 08:05AM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular offerings designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that cli(full story)
BIOC: 0.65 (-0.02)

Biocept's Target Selector(TM) ctDNA Platform

PR Newswire via COMTEX - Mon Oct 07, 08:05AM EDT
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publ(full story)
BIOC: 0.65 (-0.02)